Safety of Cosmetic Ingredients with Suspected Endocrine Disrupting Properties: call for data

Overview

The Office for Product Safety and Standards (OPSS) would like to invite any interested parties, including academia, manufacturers of cosmetic products, producers of the substances concerned and consumer associations to submit any scientific information relevant to the safety assessment of cosmetic ingredients in the list below.

OPSS would like to evaluate the safety of these ingredients in cosmetic products due to their suspected endocrine disrupting properties.

Please submit data regarding all physicochemical properties, toxicokinetic and toxicological endpoints and assessment of exposure through consumer products. Data on each individual ingredient must be provided as a separate submission.

Note: The data submitted may be subjected to the Freedom of Information Act 2000.  Any confidential and commercially sensitive data should ONLY be submitted if it is relevant to the toxicological risk assessment. Any confidential and commercially sensitive data must be very clearly marked in a submission. Any data that is not marked as confidential and /or commercially sensitive may be liable for release under an appropriate request.

List of chemicals 

1. Benzophenone-3 (CAS 131-57-7)
2. Octocrylene (CAS 6197-30-4)
3. Homosalate (CAS 118-56-9)
4. Kojic acid (CAS 501-30-4)
5. Butylated hydroxytoluene (BHT) (CAS 128-37-0)

Deadline for Submission: 31 May 2022

For further information, please email to opss.safetyassessment@beis.gov.uk

Data Protection

BEIS and the Office for Product Safety and Standards are committed to processing information in accordance with the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018 (DPA 2018).  The personal data collected on this form will be held securely and will only be used for administrative purposes. If you would like to understand what personal information the Office collects about you, how the Office uses this personal information, and what rights you have regarding your personal information, then please refer to our Privacy Notice via this link.